**U.S.
      SECURITIES AND EXCHANGE COMMISSION**




**Washington,
      D.C. 20549**


**FORM
      10-KSB**




**ANNUAL
      REPORT UNDER SECTION 13 OR 15 (d) OF THE**


**SECURITIES
      EXCHANGE ACT OF 1934**





For
      the
      fiscal year ended January 31, 2007





Commission
      file number 0-52836





**LIFESCIENCES
      OPPORTUNITIES INCORPORATED**


(Name
      of
      Small Business Issuer in its Charter)





Florida
            20-0594204(State
                or Other Jurisdiction of
            (I.R.S.
                EmployerIncorporation
                or Organization)
            Identification
                No.)925
                S. Federal Highway, Suite 600, Boca Raton,
                Florida 33309


(Address
      of Principal Executive Offices) (Zip Code)





(561)
      208-2929


(Issuer's
      Telephone Number)





Securities
      registered under Section 12(b) of the Act:





Title
      of Each Class        Name of Each Exchange on
      Which Registered


None





Securities
      registered under Section 12(g) of the Exchange Act:





Common
      Stock, $.0001 par value


(Title
      of
      Class)





Check
      whether issuer is not required to file reports pursuant to Section 13 or 15(d)
      of the Exchange Act. o




Check
      whether the issuer (1) filed all reports required to be filed by Section 13
      or
      15 (d) of the Exchange Act during the past 12 months (or for such shorter period
      that the registrant was required to file such reports), and (2) has been subject
      to such filing requirements for the past 90 days. Yes x No o




Check
      if
      there is no disclosure of delinquent filers in response to Item 405 of
      Regulation S-B contained in this form, and no disclosure will be contained,
      to
      the best of the registrant's knowledge, in definitive proxy or information
      statements incorporated by reference in Part III of this Form 10-KSB or any
      amendment to this Form 10-KSB.o




Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act). Yes x No
o




State
      issuer's revenues for its most recent fiscal year. $0




State
      the
      aggregate market value of the voting stock held by non-affiliates computed
      by
      reference to the price at which the stock was sold, or the average bid and
      asked
      prices of such stock, as of a specified date within the past 60 days.
      None.





**APPLICABLE
      ONLY TO CORPORATE REGISTRANTS**




State
      the
      number of shares outstanding of each of the issuer's classes of common equity,
      as of the latest practicable date: January 31, 2007: 45,000 Shares of Common
      Stock.





**DOCUMENTS
      INCORPORATED BY REFERENCE**




-
      None -





Transitional
      Small Business Disclosure Format (Check One) Yes o No x








Table
      of
      Contents


**PART
                  I.**
              
              1**Item
                  1 .**
              **Description
                  of Business**
              1**Item
                  2****.**
              **Description
                  of Property**
              4**Item
                  3******
              **Legal
                  Proceedings**
              4**Item
                  4****.**
              **Submission
                  of Matters to a Vote of Security Holders**
              4**PART
                  II.**
              
              5**Item
                  5****.**
              **Market
                  for Common Equity and Related Stockholder Matters and Small Business
                  Issuer Purchases of Equity Securities**
              5**Item
                  6****.**
              **Management’s
                  Discussion and Analysis of Financial Condition and Plan of
                  Operations**
              5**Item
                  7****.**
              **Financial
                  Statements**
              6**Item
                  8****.**
              **Changes
                  in and Disagreements With Accountants on Accounting and Financial
                  Disclosure**
              7**Item
                  8A.**
              **Controls
                  and Procedures**
              7**Item
                  8B**.
              **Other
                  Information**
              7**PART
                  III.**
              
              8**Item
                  9****.**
              **Directors
                  and Executive Officers, Promoters, Control Persons, and Corporate
                  Governance; Compliance with Section 16(a) of the Exchange
                  Act**
              8**Item
                  10****.**
              **Executive
                  Compensation**
              9**Item
                  11****.**
              **Security
                  Ownership of Certain Beneficial Owners and Management and Related
                  Stockholder Matters**
              9**Item
                  12****.**
              **Certain
                  Relationships and Related Transactions, and Director
                  Independence**
              10**Item
                  13****.**
              **Exhibits**
              11**Item
                  14****.**
              **Principal
                  Accountant Fees and Services**
              12





**PART
      I.**




**Item
                1**.
            
            **Description
                of Business**




**General**




We
      are a
      blank check company. A blank check company is a company that has no specific
      business plan or purpose or has indicated that its business plan is to engage
      in
      a merger or acquisition with an unidentified company or companies, or other
      entity or person. During December 2006 we completed a public offering that
      complied with the provisions of Rule 419 of the Securities Act of 1933. We
      sold
      5,000 shares on a self-underwritten basis by Roland Perry, our sole officer
      and
      director.




Rule
      419
      requires that the offering proceeds and all securities to be issued be deposited
      into an escrow or separate bank account established by a registered broker
      dealer maintaining net capital equal to or exceeding $25,000, governed by an
      agreement which contains certain terms and provisions specified by Rule 419.
      Dawson James Securities, Inc., a member of the National Association of
      Securities Dealers, Inc. (“NASD”), has established such an account on our behalf
      and we have entered into an escrow agreement with Dawson James. Dawson James
      is
      controlled by an affiliate of our company. Under Rule 419, the deposited funds
      and deposited securities will be released to us and to investors, respectively,
      only after we have met the following conditions: (1) we must execute an
      agreement for an acquisition meeting certain prescribed criteria; (2) we must
      successfully complete a reconfirmation offering which includes certain
      prescribed terms and conditions; and (3) the acquisition meeting the prescribed
      criteria must be consummated.




The
      acquisition agreement must provide for the acquisition of a business or assets
      valued at not less than $48,000. Once the acquisition agreement meeting the
      above criteria has been executed, we must successfully complete the mandated
      reconfirmation offering and consummate the acquisition. Rule 419 requires
      us to update our registration statement with a post-effective amendment. The
      post-effective amendment must contain information about: the proposed
      acquisition candidate and its business, including audited financial statements;
      the results of our initial offering; and the use of the funds disbursed from
      the
      escrow account. The post-effective amendment must also include the terms of
      the
      reconfirmation offer mandated by Rule 419.




The
      reconfirmation offer must commence within five business days after the effective
      date of the post-effective amendment. Pursuant to Rule 419, the terms of the
      reconfirmation offer must include the following conditions:




(1)  The
      prospectus contained in the post-effective amendment will be sent to each
      investor whose securities are held in the escrow account;




(2)  Each
      investor will have no fewer than 20, and no more than 45, business days from
      the
      effective date of the post-effective amendment to notify us in writing that
      the
      investor elects to remain an investor;




(3)  If
      we do
      not receive written notification from any investor within 45 business days
      following the effective date, the pro rata portion of the deposited funds (and
      any related interest or dividends) held in the escrow account on such investor's
      behalf will be returned to the investor within five business days by first
      class
      mail or other equally prompt means;




1




(4)  The
      acquisition will be consummated only if investors having contributed $48,000
      of
      the public offering proceeds elect to reconfirm their investments;
      and




(5)  If
      a
      consummated acquisition has not occurred within 18 months from the date of
      our
      Rule 419 prospectus (December 14, 2007), the deposited funds held in the escrow
      account shall be returned to all investors.




The
      deposited funds and deposited securities may be released to our company and
      the
      investors, respectively, after the escrow agent has received written
      certification from us that we have consummated an acquisition(s) of a
      business(es) the value of which represents at least 80% of the maximum offering
      proceeds and have filed the required post-effective amendment, the
      post-effective amendment has been declared effective, the mandated
      reconfirmation offer having the conditions prescribed by Rule 419 has been
      completed, and we have satisfied all of the prescribed conditions of the
      reconfirmation offer.




During
      the period covered by this report, we had not selected any particular industry
      or any acquisition in which to concentrate our business combination efforts.
      To
      the extent we effect a business combination with a financially unstable entity
      or an entity in its early stage of development or growth (including entities
      without established records of sales or earnings), we will become subject to
      numerous risks inherent in the business and operations of financially unstable
      and early stage or potential emerging growth entities. In addition, to the
      extent that we effect a business combination with an entity in an industry
      characterized by a high level of risk, we will become subject to the currently
      unascertainable risks of that industry.




**Rule
      419 Offering**




During
      December 2006, the Company closed its public offering pursuant to Rule 419
      of
      the Securities Act of 1933 and collected gross proceeds of $30,004. The funds
      are held with an escrow agent. Under the 419 Rule, the shareholders are entitled
      to have monies returned to them if they do not reconfirm the 419 merger
      candidate or eighteen months pass without the Company completing a business
      combination; therefore these funds may or may not be released to the Company.
      As
      of the date of this report, the Company did not identify a merger
      candidate.




**Subsequent
      Events**




As
      reported on Form 8-K Current Report filed on September 28, 2007, the Company
      entered into an agreement and plan of merger ("Merger Agreement") with Dr.
      TATTOFF, LLC, a California limited liability company ("TATTOFF") dated September
      7, 2007, whereby TATTOFF will be merged into the Company. Under the terms of
      the
      Merger Agreement, it is anticipated the Company will issue, on a 1 for 1 basis,
      an aggregate of approximately 8,400,000 shares of its restricted common stock
      and warrants to purchase approximately 1,005,000 shares of its common stock
      at
      an exercise price of $1.25 per share, subject to adjustment under the terms
      of
      the Merger Agreement. The common stock and warrants shall be issued on a
      post-forward split basis as described below. The closing of the merger is
      conditioned upon the Company's shareholders approving proposals to amend the
      Company's articles of incorporation to change its corporate name to Dr. TATTOFF,
      Inc. and to amend the Company's articles of incorporation to effectuate a 1
      to
      55.5 forward split of the Company's outstanding common stock. The completion
      of
      the merger will be subject to satisfaction of additional conditions described
      in
      the Merger Agreement.




2




Dr.
      TATTOFF, LLC was organized under the laws of the state of California in 2004.
      TATTOFF is a provider of marketing and practice management services to
      physicians who perform tattoo removal, hair removal services (regardless of
      method) and laser-based skin care services. TATTOFF endeavors to develop laser
      center sites and to provide turnkey marketing services, human resources and
      staffing services, patient management services, technical solutions, office
      management and other non-medical services to the physicians and medical staff
      at
      each of its laser centers. TATTOFF owns the registered trademark, Dr. TATTOFF,
      and licenses the use of the trademark as part of the management services
      provided to physicians. These services are provided directly to the physicians
      or to their medical corporations, medical groups or other affiliated entities.
      TATTOFF currently has three laser centers in Southern California: Beverly Hills,
      Irvine and Encino. For the fiscal year ended December 31, 2006 TATTOFF had
      revenues of approximately $745,571 and a net loss of approximately $419,905.
      TATTOFF's principal executive offices are located at 8447 Wilshire Boulevard,
      Suite 102, Beverly Hills, CA 90211.




**Government
      Regulation**




As
      a
      general rule, federal and state tax laws and regulations have a significant
      impact upon the structuring of business combinations. We will evaluate the
      possible tax consequences of any prospective business combination and will
      endeavor to structure the business combination so as to achieve the most
      favorable tax treatment to our company, the acquisition target and their
      respective shareholders. There can be no assurance that the IRS or appropriate
      state tax authorities will ultimately assent to our tax treatment of a
      particular consummated business combination. To the extent the IRS or state
      tax
      authorities ultimately prevail in recharacterizing the tax treatment of a
      business combination, there may be adverse tax consequences to our company,
      the
      target and their respective shareholders. Tax considerations as well as other
      relevant factors will be evaluated in determining the precise structure of
      a
      particular business combination, which could be effected through various forms
      of a merger, consolidation or stock or asset acquisition.




Under
      the
      federal securities laws, public companies must furnish certain information
      about
      significant acquisitions, which information may require audited financial
      statements of an acquired entity with respect to one or more fiscal years,
      depending upon the relative size of the acquisition. Consequently, we will
      not
      seek to consummate a business combination with any target unable to provide
      audited financial statements.




**Investment
      Company Act**




Our
      operations may be limited by the Investment Company Act. Unless we register
      with
      the SEC as an investment company, we will not, among other things, be permitted
      to own investment securities, exclusive of government securities and cash items,
      which have a value exceeding 40% of the value of our total assets on an
      unconsolidated basis. While we may participate in a business opportunity by
      purchasing, trading or selling the securities of an entity, we do not intent
      to
      engage primarily in trading activities. We intend to conduct our operations
      so
      as not to require registration under the Investment Company Act.




3


**Competition**




We
      expect
      to encounter substantial competition in our efforts to locate attractive
      opportunities, primarily from business development companies, venture capital
      partnerships and corporations, venture capital affiliates of large industrial
      and financial companies, small investment companies, and wealthy individuals.
      Many of these entities will have significantly greater experience, resources
      and
      managerial capabilities than our company and will therefore be in a better
      position than us to obtain access to attractive business opportunities. We
      also
      will experience competition from other blank check companies, many of which
      may
      have more funds available than we do.




In
      the
      event that we succeed in effecting a business combination, we will, in all
      likelihood, become subject to intense competition from competitors of the
      acquisition target. In particular, certain industries, which experience rapid
      growth frequently, attract an increasingly larger number of competitors,
      including competitors with increasingly greater financial, marketing, technical
      and other resources than the initial competitors in the industry. The degree
      of
      competition characterizing the industry of any prospective target cannot
      presently be ascertained. There can be no assurance that, subsequent to a
      business combination, we will have the resources to compete effectively,
      especially to the extent that the target is in a high growth
      industry.




**Employees**




As
      of the
      date of this report, our employees consist of our executive officer. He has
      devoted approximately 20% of his working time to our affairs since completing
      our offering.




**Item
                2****.**
            
            **Description
                of Property**




Pursuant
      to an oral agreement with Ark Financial Services, Inc., we occupy executive
      offices rent-free in approximately 1,100 square feet of office space located
      at
      925 S. Federal Highway, Suite 600, Boca Raton, Florida 33432. We intend to
      occupy this space until we effect a business combination. We consider this
      space
      to be adequate for our needs and have no preliminary agreements or
      understandings with respect to office space in the future, although Ark
      Financial Services has orally agreed to permit us to occupy this space until
      we
      effect a business combination.




**Item
                3****.**
            
            **Legal
                Proceedings**




None.




**Item
                4****.**
            
            **Submission
                of Matters to a Vote of Security
                Holders**




None.




4


**PART
      II.**




**Item
                5****.**
            
            **Market
                for Common Equity and Related Stockholder Matters and Small Business
                Issuer Purchases of Equity
                Securities**




**General**




There
      is
      no trading market for Lifesciences common stock at present and there has been
      no
      trading to date. Management has not undertaken any discussions with any
      prospective market maker concerning the participation in the aftermarket for
      our
      securities and management does not intend to initiate any discussions until
      we
      have consummated a merger or acquisition. We cannot guarantee that a trading
      market will ever develop, or if a market does develop, that it will continue.
      At
      January 31, 2007, Lifesciences has two shareholders, and an additional seven
      potential shareholders who must decide whether or not to reconfirm their
      investment before they can become shareholders.




**Dividends**




We
      have
      not paid a cash dividend on the common stock since our inception. The payment
      of
      dividends may be made at the discretion of our board of directors and will
      depend upon, among other things, our operations, our capital requirements and
      our overall financial condition. As of the date of this report, we have no
      intention to declare dividends.




**Other
      Stockholders Matters**




Pursuant
      to a registration statement on Form SB-2 dated June 7, 2006, the Company
      executed subscription agreements for the sale of an aggregate of 5,000 shares
      of
      common stock to seven investors and raised gross proceeds of $30,004. The
      offering was completed during December 2006. The Company has access to 10%
      of
      the gross proceeds, but has not accessed such funds. Pursuant to Rule 419 of
      the
      Securities Act the proceeds and all shares of common stock to be issued have
      been deposited into an escrow account.




**Small
      Business Issuer Purchase of Equity Securities**




None.




**Item
                6****.**
            
            **Management’s
                Discussion and Analysis of Financial Condition and Plan of
                Operations**




**General**




Management's
      discussion and analysis contains various forward-looking statements. These
      statements consist of any statement other than a recitation of historical fact
      and can be identified by the use of forward-looking terminology such as "may,"
      "expect," "anticipate," "estimate" or "continue" or use of negative or other
      variations or comparable terminology.




We
      caution that these statements are further qualified by important factors that
      could cause actual results to differ materially from those contained in the
      forward-looking statements, that these forward-looking statements are
      necessarily speculative, and there are certain risks and uncertainties that
      could cause actual events or results to differ materially from those referred
      to
      in such forward-looking statements.




5


**Plan
      of Operations**




The
      Company intends to seek to acquire assets or shares of an entity actively
      engaged in a business that generates revenues, in exchange for its securities.
      During December 2006, the Company closed its Rule 419 offering and collected
      gross proceeds of $30,004, which are currently held with an escrow agent. Under
      Rule 419, the shareholders are entitled to have monies returned to them if
      they
      do not reconfirm the 419 merger candidate or eighteen months pass from the
      date
      of the Company's registration statement without finding a merger candidate;
      therefore these funds may or may not be released to the Company. As of the
      date
      of this report, the Company had not identified a merger candidate.




Due
      to
      the Company's intent to remain a shell corporation until a merger or acquisition
      candidate is identified, it is anticipated that its cash requirements shall
      be
      minimal, and that all necessary capital, to the extent required, will be
      provided by the Company's sole officer/director or other affiliates. The Company
      also does not expect to acquire any plant or significant equipment.




Our
      initial offering was a "blank check" offering due to the fact that we are a
      development stage company that has no specific business plan or purpose and
      we
      indicated that our business plan or purpose was to merge with or be acquired
      by
      an unidentified company.




Once
      a
      merger candidate is identified we are required to file a post-effective
      amendment to our registration statement on Form SB-2 (File No-333-117100)
      detailing the proposed combination and requesting a reconfirmation from
      stockholders that purchased shares in its public offering to reconfirm their
      election to invest in the Company's shares. The post-effective amendment is
      required to contain information about our proposed merger candidate and its
      business, including audited financial statements and the proposed use of the
      funds to be disbursed from the escrow account.




Our
      reconfirmation offering is subject to Rule 419 under the Securities Act, and
      the
      post-effective amendment will also include the terms of the reconfirmation
      offer
      mandated by Rule 419. Among other things, the fair market value of the business
      or assets must represent at least 80% of the maximum proceeds of our prior
      offering. For purposes of this blank check offering, the fair market value
      of
      the business or assets to be acquired must be at least $48,000.




The
      offering proceeds and shares held in escrow may be released to us and the
      investors, respectively, after the escrow agent has received a signed
      representation from us and any other evidence acceptable by the escrow agent
      that:




(1)  We
      have
      executed a Merger Agreement and that the fair value of the business represents
      at least $48,000, and we have filed the required post-effective
      amendment;




(2)  The
      post-effective amendment has been declared effective, the mandated
      reconfirmation offer prescribed by Rule 419 has been completed and we have
      satisfied all of the prescribed conditions of the reconfirmation
      offer.


The
      Company has no full time employees. Our sole officer has agreed to allocate
      a
      portion of his time to the activities of the Company, without compensation.
      This
      officer anticipates that the business plan of the Company can be implemented
      by
      devoting approximately 10 hours per month to the business affairs of the Company
      and, consequently, conflicts of interest may arise with respect to the limited
      time commitment by such officer. The Company does not expect any changes in
      the
      number of employees until a business combination is completed.




We
      currently rely on advances from our affiliates for working capital. Our
      affiliates have advanced our company working capital to cover expenses. Advances
      are non-interest bearing and repayable on or before 24 months from the date
      of
      the advance. Repayment of advances will not be a condition completing an
      acquisition.




**Item
                7****.**
            
            **Financial
                Statements**




The
      financial statements required by this report are included, commencing on
      F-1.


6




Lifesciences
      Opportunities, Inc.





FINANCIAL
      STATEMENTS








Table
      of
      Contents








Report
                of Independent Certified Public Accountants
            F
                -
                2Balance
                Sheets
            F
                -
                3Statements
                of Operations
            F
                -
                4Statements
                of Changes in Shareholders’ Deficit
            F
                -
                5Statements
                of Cash Flows
            F
                -
                6Notes
                to Financial Statements
            F
                -
                7 -11





F-1





Report
      of Independent Registered Public Accounting Firm














To
      the
      shareholders and board of directors


Lifesciences
      Opportunities Incorporated:





We
      have
      audited the accompanying balance sheets of Lifesciences Opportunities, Inc.
      as
      of January 31, 2007 and 2006, and the related statements of income,
      shareholders’ deficiency and cash flows for periods then ended. These financial
      statements are the responsibility of the Company’s management. Our
      responsibility is to express an opinion on these financial statements based
      on
      our audits.





We
      conducted our audits in accordance with the standards of the Public Company
      Accounting Oversight Board (United States). Those standards require that we
      plan
      and perform the audit to obtain reasonable assurance about whether the financial
      statements are free of material misstatement. The Company is not required to
      have, nor were we engaged to perform, an audit of its internal control over
      financial reporting. Our audit included consideration of internal control over
      financial reporting as a basis for designing audit procedures that are
      appropriate in the circumstances, but not for the purpose of expressing an
      opinion on the effectiveness of the Company’s internal control over financial
      reporting. Accordingly, we express no such opinion. An audit also includes
      examining, on a test basis, evidence supporting the amounts and disclosures
      in
      the financial statements, assessing the accounting principles used and
      significant estimates made by management, as well as evaluating the overall
      financial statement presentation. We believe that our audits provide a
      reasonable basis for our opinion.





In
      our
      opinion, the financial statements referred to above present fairly, in all
      material respects, the financial position of Lifesciences Opportunities, Inc.
      as
      of January 31, 2007 and 2006, and the results of its operations and its cash
      flows for the periods then ended in conformity with accounting principles
      generally accepted in the United States of America.





The
      accompanying financial statements referred to above have been prepared assuming
      that the Company will continue as a going concern. As more fully described
      in
      Note 1, the Company’s need to seek new sources or methods of financing or
      revenue to pursue its business strategy, raise substantial doubt about the
      Company’s ability to continue as a going concern. Management’s plans as to these
      matters are also described in Note 1. The financial statements do not include
      any adjustments that might result from the outcome of this uncertainty.








JEWETT,
      SCHWARTZ, WOLFE & ASSOCIATES





HOLLYWOOD,
      Florida,


September
      24, 2007




F-2


LIFESCIENCES
                  OPPORTUNITIES INCORPORATEDBALANCE
                  SHEETSJanuary
                  31,
              
              January
                  31,2007
              
              2006(Audited)
              
              (Audited)ASSETSCURRENT
                  ASSETSCash
              
              $
              6
              
              $
              40TOTAL
                  CURRENT ASSETS
              
              
              6
              
              
              40OTHER
                  ASSETSRestricted
                  cash
              
              
              30,122
              
              
              -TOTAL
                  ASSETS
              
              $
              30,128
              
              $
              40LIABILITIES
                  AND SHAREHOLDERS' DEFICITCURRENT
                  LIABILITIESAccounts
                  payable
              
              $
              3,894
              
              $
              -Accrued
                  expenses
              
              
              15,225
              
              
              -Loan
                  from shareholders
              
              
              9,100
              
              
              4,500TOTAL
                  CURRENT LIABILITIES
              
              
              28,219
              
              
              4,500TOTAL
                  LIABILITIES
              
              
              28,219
              
              
              4,500Commitments
                  and contingencies
              
              
              -
              
              
              -SHAREHOLDERS'
                  DEFICITCommon
                  stock, $0.0001 par value,80,000,000
                  shares authorized,40,000
                  shares issued and outstanding
              
              
              4
              
              
              4Additional
                  paid-in capital
              
              
              4,996
              
              
              4,996Stock
                  subscription received
              
              
              30,004
              
              
              -Accumulated
                  deficit
              
              
              (33,095
              )
              
              (9,460
              )TOTAL
                  SHAREHOLDERS' DEFICIT
              
              
              1,909
              
              
              (4,460
              )TOTAL
                  LIABILITIESAND
                  SHAREHOLDERS' DEFICIT
              
              $
              30,128
              
              $
              40
  F-3
 LIFESCIENCES
                    OPPORTUNITIES INCORPORATEDSTATEMENTS
                    OF OPERATIONSFor
                    the periods endedJanuary
                    31,
                
                January
                    31,2007
                
                2006(Audited)
                
                (Audited)REVENUES
                
                $
                -
                
                $
                -OPERATING
                    EXPENSES
                
                
                23,841
                
                
                1,711LOSS
                    FROM OPERATIONS
                
                
                (23,841
                )
                
                (1,711
                )OTHER
                    INCOME (EXPENSES)
                
                
                206
                
                
                -INCOME
                    (LOSS) BEFORE TAXES
                
                
                (23,635
                )
                
                -INCOME
                    TAXES
                
                
                -
                
                
                -NET
                    LOSS
                
                $
                (23,635
                )
                $
                (1,711
                )Weighted
                    average commonshares
                    outstanding - basic and diluted
                
                
                40,000
                
                
                40,000NET
                    LOSS PER SHARE - basic and diluted
                
                $
                (0.59
                )
                $
                (0.04
                )
 
 F-4
  LIFESCIENCES
        OPPORTUNITIES INCORPORATED
  STATEMENTS
        OF CHANGES IN SHAREHOLDERS' DEFICIT
 Common
                    Stock
                
                
                
                Common80,000,000
                    shares authorized
                
                Additional
                
                StockShares
                
                Par
                    Value
                
                Paid-in
                
                Subscriptions
                
                AccumulatedIssued
                
                $.0001
                    per share
                
                Capital
                
                Receivable
                
                Deficit
                
                TotalBALANCE
                    - JANUARY 31, 2005 (Audited)
                
                
                40,000
                
                $
                4
                
                $
                4,996
                
                $
                -
                
                $
                (7,749
                )
                $
                (2,749
                )Net
                    Loss
                
                
                
                
                
                -
                
                
                -
                
                
                -
                
                
                (1,711
                )
                
                (1,711
                )BALANCE
                    - JANUARY 31, 2006 (Audited)
                
                
                40,000
                
                $
                4
                
                $
                4,996
                
                $
                -
                
                $
                (9,460
                )
                $
                (4,460
                )Proceeds
                    from stock subscriptions
                
                
                
                
                
                -
                
                
                -
                
                
                30,004
                
                
                -
                
                
                30,004Net
                    Loss
                
                
                
                
                
                -
                
                
                -
                
                
                -
                
                
                (23,635
                )
                
                (23,635
                )BALANCE
                    - JANUARY 31, 2007 (Audited)
                
                
                40,000
                
                $
                4
                
                $
                4,996
                
                $
                30,004
                
                $
                (33,095
                )
                $
                1,909
 
 F-5
 LIFESCIENCES
                    OPPORTUNITIES INCORPORATEDSTATEMENTS
                    OF CASH FLOWSFor
                    the periods endedJanuary
                    31,
                
                January
                    31,2006
                
                2005Cash
                    flows from operating activitiesNet
                    loss
                
                $
                (23,635
                )
                $
                (1,711
                )Adjustments
                    to reconcile net loss to netcash
                    used in operating activities:Increase
                    in restricted cash
                
                
                (30,122
                )
                
                -Increase
                    in accounts payable
                
                
                3,894
                
                
                -Increase
                    in accrued expenses
                
                
                15,225
                
                
                (2,313
                )Net
                    cash used by operating activities
                
                
                (34,638
                )
                
                (4,024
                )Cash
                    flows from financing activitiesProceeds
                    from shareholder loan
                
                
                4,600
                
                
                3,900Issuance
                    of common stock subscriptions
                
                
                30,004
                
                
                -Net
                    cash provided by financing activities
                
                
                34,604
                
                
                3,900NET
                    INCREASE (DECREASE) IN CASH
                
                
                (34
                )
                
                (124
                )CASH
                    AT BEGINNING OF PERIOD
                
                
                40
                
                
                164CASH
                    AT END OF PERIOD
                
                $
                6
                
                $
                40


F-6
 LIFESCIENCES
              OPPORTUNITIES INCORPORATED
 NOTES
              TO
              THE FINANCIAL STATEMENTS
 JANUARY
              31, 2007 AND 2006





NOTE
      1 -
      ORGANIZATION AND GOING CONCERN





Lifesciences
      Opportunities, Inc. (the “Company”) was incorporated under the laws of the State
      of Florida on January 12, 2004, to engage in any lawful corporate undertaking,
      including, but not limited to, selected mergers and acquisitions. The Company
      has had no operations to date other than issuing shares to its original
      shareholder.





The
      Company has been formed to provide a method for a foreign or domestic private
      company to become a reporting ("public") company whose securities are qualified
      for trading in the United States secondary market.





The
      Company will attempt to locate and negotiate with a business entity for the
      combination of that target company with us. The combination will normally take
      the form of a merger, stock-for-stock exchange or stock-for-assets exchange.
      No
      assurances can be given that we will be successful in locating or negotiating
      with any target company.





These
      financial statements have been prepared assuming that the Company will continue
      as a going concern. The Company’s independent accountants have included a “going
      concern” paragraph in their audit report accompanying these financial statements
      that cautions users of the statements that the Company needs to seek new sources
      or methods of financing or revenue to pursue its business strategy. The
      financial statements do no include any adjustments that might result from the
      outcome of this uncertainty. The Company anticipates that future revenue will
      be
      sufficient to cover certain operating expenditures, and, in the interim, will
      continue to pursue additional capital investment. However, there can be no
      assurance that the Company will be able to successfully acquire the necessary
      capital investment or revenue to continue their on-going efforts and continue
      operations. These factors, among others, create an uncertainty about the
      Company’s ability to continue as a going concern.





NOTE
      2 -
      SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES





Revenue
      Recognition





The
      Company has adopted and follows the guidance provided in the Securities and
      Exchange Commission’s Staff Accounting Bulletin (“SAB”) No. 104, which provides
      guidance on the recognition, presentation and disclosure of revenue in financial
      statements.





Use
      of
      Estimates





The
      preparation of financial statements in conformity with generally accepted
      accounting principles requires management to make estimates and assumptions
      that
      affect the reported amounts of assets and liabilities, and disclosure of
      contingent assets and liabilities, at the date of these financial statements,
      and the reported amounts of revenues and expenses during the reporting period.
      Actual results could differ from those estimates.








F-7
 LIFESCIENCES
            OPPORTUNITIES INCORPORATED
 NOTES
            TO
            THE FINANCIAL STATEMENTS
 JANUARY
            31, 2007 AND 2006





Cash





The
      Company considers all highly liquid debt securities purchased with original
      or
      remaining maturities of three months or less to be cash equivalents. The
      carrying value of cash equivalents approximates fair value.





Income
      Taxes





The
      Company uses the asset and liability method of accounting for income taxes
      as
      required by the Financial Accounting Standards Board (FASB) Statement on
      Financial Accounting Standards (SFAS) No. 109, “Accounting for Income Taxes”.
      SFAS No. 109 requires the recognition of deferred tax assets and liabilities
      for
      the expected future tax consequences of temporary differences between the
      carrying amounts and the tax basis of certain assets and liabilities. Deferred
      income taxes arise from timing differences resulting from income and expense
      items reported for financial accounting and tax purposes in different periods. ****** A
      deferred tax asset valuation allowance is recorded when it is more likely than
      not that deferred tax assets will not be realized.





Utilization
      of the net operating loss carry-forwards may be subject to a substantial annual
      limitation due to ownership change limitations provided by the Internal Revenue
      Code. The annual limitation may result in the expiration of net operating loss
      carry-forwards before utilization.





Loss
      Per Share





The
      Company computes basic and diluted loss per share amounts pursuant to Statement
      of Financial Accounting Standards (SFAS) No. 128, “Earnings per Share.” There
      are no potentially dilutive shares outstanding and, accordingly, dilutive per
      share amounts are the same as basic per share amounts.





Recent
      Accounting Pronouncements




In
      February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for
      Financial Assets and Financial Liabilities - Including an amendment of FASB
      Statement No. 115” (SFAS 159), which becomes effective for the Company on
      February 1, 2008, permits companies to choose to measure many financial
      instruments and certain other items at fair value and report unrealized gains
      and losses in earnings. Such accounting is optional and is generally to be
      applied instrument by instrument. The Company does not anticipate that the
      election, of this fair-value option will have a material effect on its financial
      condition, results of operations, cash flows or disclosures.






In
      September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements" (SFAS
      157). SFAS 157 provides guidance for using fair value to measure assets and
      liabilities. SFAS 157 addresses the requests from investors for expanded
      disclosure about the extent to which companies measure assets and liabilities
      at
      fair value, the information used to measure fair value and the effect of fair
      value measurements on earnings. SFAS 157 applies whenever other standards
      require (or permit) assets or liabilities to be measured at fair value, and
      does
      not expand the use of fair value in any new circumstances. SFAS 157 is effective
      for financial statements issued for fiscal years beginning after November 15,
      2007 and will be adopted by the Company in the first quarter of fiscal year
      2009. The Company is unable at this time to determine the effect that its
      adoption of SFAS 157 will have on its results of operations and financial
      condition.




F-8
 LIFESCIENCES
            OPPORTUNITIES INCORPORATED
 NOTES
            TO
            THE FINANCIAL STATEMENTS
 JANUARY
            31, 2007 AND 2006







In
      June
      2006, the FASB issued FASB interpretation No. 48 “Accounting for Uncertain Tax
      Positions - An Interpretation of FASB Statement No. 109” (“FIN 48”). FIN 48
      clarifies the accounting for uncertainty in income taxes recognized in an
      enterprise’s financial statements in accordance with the SFAS No. 109
“Accounting for Income Taxes”. It prescribes a recognition threshold and
      measurement attribute for the financial statement recognition and measurement
      of
      a tax position taken or expected to be taken in a tax return. FIN 48 also
      provides guidance on derecognition, classification, interest and penalties,
      accounting in interim periods, disclosure, and transition. FIN 48 is effective
      for fiscal years beginning after December 15, 2006. The Company is currently
      evaluating the impact, if any, of FIN 48 to its financial position and results
      of operations






In
      May
      2005, the FASB issued SFAS No. 154, "Accounting Changes and Error Corrections"
      (SFAS 154), which replaces Accounting Principles Board (APB) Opinion No. 20,
      "Accounting Changes," and SFAS No. 3, "Reporting Accounting Changes in Interim
      Financial Statements - An Amendment of APB Opinion No. 28." SFAS 154 provides
      guidance on the accounting for and reporting of accounting changes and error
      corrections, and it establishes retrospective application, or the latest
      practicable date, as the required method for reporting a change in accounting
      principle and the reporting of a correction of an error. SFAS 154 is effective
      for accounting changes and corrections of errors made in fiscal years beginning
      after December 15, 2005. The Company adopted SFAS 154 in the first quarter
      of
      fiscal year 2007 and does not expect it to have a material impact on its results
      of operations and financial condition.




NOTE
      3 - RESTRICTED CASH





Restricted
      cash as of January 31, 2007 is comprised of $30,122 received from stock
      subscriptions and placed in an escrow account subject to the provisions of
      the
      initial public offering as described in Note 6.





NOTE
      4 - RELATED PARTY TRANSACTIONS





The
      loan from shareholders as of January 31, 2007 and 2006 are $9,100 and $4,500,
      respectively. The notes are interest free and the Company imputed interest
      in
      accordance with the provisions of Accounting Principles Board Opinion (APBO)
      No:
      21. “Interest on Receivables and Payables”. Accordingly, the interest expense
      for January 31, 2007 is $510. The average interest rate used for the periods
      was
      4.43%.




F-9
 LIFESCIENCES
            OPPORTUNITIES INCORPORATED
 NOTES
            TO
            THE FINANCIAL STATEMENTS
 JANUARY
            31, 2007 AND 2006





NOTE
      5 - ACCRUED EXPENSES





Accrued
      expenses as of January 31, 2007 and 2006 are as follows


2007
              
              2006Audit
                  fees
              
              $
              12,500
              
              $
              -Legal
                  fees
              
              
              2,215
              
              
              -Interest
                  expenses
              
              $
              510
              
              $
              -Total
                  accrued expenses
              
              $
              15,225
              
              $
              -







NOTE
      6 - COMMON STOCK SUBSCRIBED





In
      June,
      2006 the Company conducted a "blank check" offering subject to Rule 419 of
      Regulation C as promulgated by the U.S. Securities and Exchange Commission
      (SEC)
      under the Securities Act of 1933, as amended. The offering proceeds and the
      securities to be issued to investors must be deposited in an escrow account.
      While held in the escrow account, the deposited securities may not be traded
      or
      transferred. Except for an amount up to 10% of the deposited funds otherwise
      releasable under Rule 419, the deposited funds and the deposited securities
      may
      not be released until an acquisition meeting certain specified criteria has
      been
      consummated and a sufficient number of investors reconfirm their investment
      in
      accordance with the procedures set forth in Rule 419. Pursuant to these
      procedures, a new prospectus, which describes an acquisition candidate and
      its
      business and includes audited financial statements, will be delivered to all
      investors. The Company must return the pro rata portion of the deposited funds
      to any investor who does not elect to remain an investor. Unless a sufficient
      number of investors elect to remain investors, all investors will be entitled
      to
      the return of a pro rata portion of the deposited funds (plus interest, if
      any)
      and none of the deposited securities will be issued to investors. In the event
      an acquisition is not consummated within 18 months of the effective date of
      this
      prospectus, the deposited funds will be returned on a pro rata basis to all
      investors.





The
      filing was declared to be effective by SEC on June 14, 2006. The Company offered
      10,000 shares through this offering of which 5,000 shares has been subscribed
      for as of January 31, 2007. The Company has placed the entire proceeds of
      $30,004 from the sale of the shares in an Escrow Account and 90% of the proceeds
      are subject to release upon the earlier of (1) written notification by the
      Company of the need for all, or substantially all, of such net proceeds for
      the
      purpose of facilitating a business combination; or (2) 18 months after the
      effective date of this registration statement.





No
      funds
      will be disbursed from the escrow account for the payment of salaries or
      reimbursement of expenses incurred by our officers and directors. In no event
      will the escrowed funds be used for any purpose other than implementation of
      a
      business combination.





F-10
 LIFESCIENCES
            OPPORTUNITIES INCORPORATED
 NOTES
            TO
            THE FINANCIAL STATEMENTS
 JANUARY
            31, 2007 AND 2006





NOTE
      7 - SUBSEQUENT EVENTS





During
      September 2007, the Company entered into an agreement and plan of merger
      ("Merger Agreement") with Dr. TATTOFF, LLC, a California limited liability
      company, ("TATTOFF"), whereby TATTOFF will be merged into the Company. Under
      the
      terms of the Merger Agreement, the Company will issue up to 8,400,000 shares
      of
      its restricted common stock and common stock purchase warrants to purchase
      up to
      an aggregate of 1,005,000 shares of the Company's common stock, exercisable
      at
      $1.25 per share subject to adjustment. The common stock and warrants shall
      be
      issued on a post-forward split basis as described below. In addition to
      complying with Rule 419 requirements, the closing of the merger is conditioned
      upon the Company's shareholders approving proposals to amend the Company's
      articles of incorporation to change its corporate name to Dr. TATTOFF, Inc.
      and
      to amend the Company's articles of incorporation to effectuate a 1 to 55.5
      forward split of the Company's outstanding common stock. The completion of
      the
      merger will be subject to satisfaction of additional conditions described under
      the Merger Agreement.




F-11




**Item
                8****.**
            
            **Changes
                in and Disagreements With Accountants on Accounting and Financial
                Disclosure**




None.


**Item
                        8A.**
                    **Controls
                        and Procedures**


Evaluation
      of disclosure controls and procedures




As
      of the
      end of the period covered by this report, we carried out an evaluation of the
      effectiveness of the design and operation of our disclosure controls and
      procedures pursuant to Exchange Act Rule 13a-14. This evaluation was done under
      the supervision and with the participation of our Principal Executive Officer
      and Principal Financial Officer. Based upon that evaluation, our Principal
      Executive Officer and Principal Financial Officer concluded that our disclosure
      controls and procedures are not effective due to the Company’s failure to timely
      file its quarterly reports and annual report with the SEC. This weakness is
      due
      to the Company’s lack of staffing, as the Company is a “blank check” company
      with one officer/employee that devotes limited time to the Company’s business.
      We believe that the weakness will be resolved once the Company completes its
      reorganization.




Changes
      in internal controls




There
      were no changes in our internal controls or in other factors that could
      significantly affect those controls since the most recent evaluation of such
      controls.


**Item
                      8B.**
                  **Other
                      Information**


None.




7


**PART
      III.**




**Item
                9****.**
            
            **Directors
                and Executive Officers, Promoters, Control Persons, and Corporate
                Governance; Compliance with Section 16(a) of the Exchange
                Act**




**Directors
      and Executive Officers**




The
      following sets forth the names and ages of our officers and directors. Our
      directors are elected annually by our shareholders, and the officers are
      appointed annually by our board of directors.


Name
              Age
              PositionRoland
                  Rick Perry
              48
              President
                  and Director




**Roland
      Rick Perry.** Mr.
      Perry
      currently serves as president of Internet PR Group, a public relations and
      independent research and consulting firm based in California. Mr. Perry has
      served as president of Institutional Analyst, Inc. (formerly known as Internet
      PR Group) since 1998. Mr. Perry attended Southern Illinois University, Loyola
      of
      Chicago and University of California, Los Angeles.




Our
      directors hold office until the next annual meeting of the shareholders and
      until their successors have been elected and qualified.




The
      directors receive no compensation for serving as such, other than reimbursement
      of reasonable expenses incurred in attending meetings. Officers are appointed
      by
      the board of directors and serve at the discretion of the board. Mr. Perry,
      the
      current executive officer of our company, intends to devote approximately 20%
      of
      his time to our affairs.




There
      are
      no agreements or understandings for any officer or director to resign at the
      request of another person and neither of the officers or directors is acting
      on
      behalf of or will act at the direction of any other person.




**Board
      of Directors and Committees**




During
      the year ended January 31, 2007, our board of directors held four meetings.




To
      date,
      we have not established an audit committee, however, the Company’s board of
      directors acts as an audit committee. We have not established a compensation
      committee nor nominating committee.




**Executive
      Compensation**




No
      compensation has been paid to any officers or directors since inception. We
      do
      not expect to pay any direct or indirect compensation to our current officers
      and directors. There are no understandings or arrangements otherwise relating
      to
      compensation.




8


**Section
      16(a) of the Exchange Act**




Section
      16(a) of the Securities Exchange Act of 1934 requires our directors and
      executive officers, and persons who own more than ten percent of our outstanding
      common stock to file with the SEC initial reports of ownership and reports
      of
      changes in ownership of common stock. These persons are required by SEC
      regulation to furnish us with copies of the reports they file.




Section
      16(a) filing requirements applicable to our officers, directors and greater
      than
      ten percent beneficial owners were not complied with on a timely basis for
      the
      period which this report relates. None of these persons filed reports during
      the
      period covered by this report.


**Item
                  10****.**
              
              **Executive
                  Compensation**


The
      table
      below sets forth compensation for the past two years awarded to, earned by
      or
      paid to our chief executive officer and each executive officer whose
      compensation exceeded $100,000 for the year ended January 31, 2007.




**Summary
      Compensation Table**


Name
                  and Principal Position
              Year
              Salary
                ($)
              Bonus
                ($)
              Stock
                Awards
                ($)
              Option
                Awards
                ($)
              Non-Equity
                Incentive
                  Plan
                Compensation
                ($)
              Nonqualified
                  Deferred Compensation
                Earnings
                ($)
              All
                  Other
                Compensation
                ($)
              Total
                ($)Roland
                  Perry,
              2007
              $0
              --
              --
              --
              --
              --
              --
              $0CEO
                  and Principal
              2006
              $0
              --
              --
              --
              --
              --
              --
              $0Financial
                  Officer




**2007
      Outstanding Equity Awards At Fiscal Year-End**




None.




**2007
      Option and Stock Grants**




None.




**Employment
      agreements**




None.




**Director
      Compensation**




Directors
      are not presently compensated by our Company.


**Item
                  11****.**
              
              **Security
                  Ownership of Certain Beneficial Owners and Management and Related
                  Stockholder Matters**




9


**Beneficial
      Ownership**




The
      following table sets forth information as of October 10, 2007 and reflects
      the
      sale of 5,000 shares in escrow pursuant to Rule 419, based on information
      obtained from the persons named below, with respect to the beneficial ownership
      of shares of common stock by (1) each person known by us to be the owner of
      more
      than 5% of the outstanding shares of common stock, (2) each director, and (3)
      officers and directors as a group. Unless otherwise indicated, the address
      of
      each of the individuals and entities below is 925 S. Federal Highway, Suite
      600,
      Boca Raton, Florida 33432.




NumberName
                  and Address
              of
                  Shares
              PercentageRoland
                  Rick Perry
              7,425
              
              17%Ark
                  Venture Capital, Inc.(1)
              14,575
              
              32%Klobnak
                  Irrevocable Trust (2)
              9,000
              
              20%John
                  J. and Valerie J.S. Klobnak (3)
              8,024
              
              18%Officers
                  and Directors as
              7,425
              
              17%a
                  group (1 persons)





(1)
      Voting control of Ark Venture Capital, Inc. is held by Robert D. Keyser and
      Albert J. Poliak, the founders and former officers and directors of our
      company.




(2)
      The
      address of the Klobnak Irrevocable Trust is 16 Briarcliff, St. Louis, Missouri
      63124. Voting control is held by Travis Aylward.




(3)
      It is
      anticipated that upon completion of the proposed merger, John J. Klobnak will
      be
      appointed to serve as member and Chairman of the Board of Directors of the
      Company. Mr. Klobnak’s address is 229 North Spoede Road, St. Louis, Missouri
      63124.




**Securities
      Authorized for Issuance Under Equity Compensation Plans**




None.


**Item
                  12****.**
              
              **Certain
                  Relationships and Related**Transactions, and Director
                  Independence****




Messrs.
      Keyser and Poliak, our former executive officers, also serve as executive
      officers for Ark Venture Capital, our majority shareholder. Effective August
      15,
      2005, Messrs. Keyser and Poliak resigned as officers and directors of our
      company. Simultaneous with their resignations, they appointed Roland Perry
      to
      serve as sole director, chief executive officer, chief financial officer and
      president of our company.




At
      January 31, 2007, affiliates had advanced our company $9,100 pursuant to oral
      agreements with the company.




Upon
      our
      inception, we issued 40,000 shares of our common stock to Ark Venture Capital,
      Inc. in consideration of $5,000. Ark Venture Capital paid approximately $0.125
      per share. In addition, Ark Venture Capital has advanced our company $9,100
      as
      of January 31, 2007. These advances are non-interest bearing and payable on
      demand. Our former officers and directors are the principal shareholders and
      executive officers of Ark Venture Capital and maintain voting control over
      Ark
      Venture Capital.




10




Effective
      August 15, 2005, Mr. Perry purchased 13,500 shares of our common stock from
      Ark
      Venture Capital in consideration of $2,025. Our company did not receive any
      proceeds from this transaction.




Since
      inception, our company, pursuant to an oral agreement with Ark Financial
      Services, Inc., has maintained at no cost to us, our executive offices. The
      offices are in approximately 1,100 square feet of office space located at 925
      S.
      Federal Highway, Suite 600, Boca Raton, Florida 33432. Mr. Poliak and Mr. Keyser
      are executive officers and principal shareholders of Ark Financial
      Services.




The
      proceeds of our Rule 419 offering are held in a non-interest bearing escrow
      account. Pursuant to Rule 419, Dawson James Securities, Inc. has established
      a
      separate bank account on our behalf. Dawson James is controlled by Ark Financial
      Services, Inc. Our former officers and directors control Ark Financial Services.
      We do not compensate Dawson James for its services.




On
      May
      16, 2007, Roland Perry sold 6,048 shares of our common stock to John J. Klobnak
      in consideration of $3,037.50. On May 16, 2007, Ark Venture Capital sold 11,925
      shares of our common stock to John J. Klobnak in consideration of $5,962.50.
      The
      Company was not a party to these transfers. Mr. Klobnak subsequently transferred
      9,000 shares to the Klobnak Irrevocable Trust. Mr. Klobnak disclaims any
      beneficial interest in the trust.




The
      Company has no independent directors.


**Item
                  13****.**
              
              **Exhibits**




(a)
            Exhibit No.
            Description of Exhibit  2.1
            Agreement
                and Plan of Merger by and among Lifesciences Opportunities Incorporated
                and Dr.Tattoff, LLC, dated September 7, 2007
                (1)


3.1
            Articles
                of Incorporation(2)


3.2
            Bylaws(2)


31.1
            Rule
                13a-14(a)/15d-4(a) Certification of Principal Financial
                Officer


31.2
            Rule
                13a-14(a)/15d-4(a) Certification of Principal Financial
                Officer 32.1
            Section 1350 Certification of Principal Executive
              Officer 32.2
            Section 1350 Certification of Principal Financial
              Officer





(1)  Previously
      filed as an exhibit to the Current Report on Form 8-K filed on October 1,
      2007.




(2)  Previously
      filed under Form SB-2 Registration Statement (333-1178100)


11


**Item
                  14****.**
              
              **Principal Accountant Fees and
                Services**




**Year
      ended January 31, 2007**




Audit
      Fees:   The aggregate fees, including expenses, billed by our current
      principal accountant in connection with the audit of our consolidated financial
      statements for the most recent fiscal year and for the review of our financial
      information included in our Annual Report on Form 10-KSB for the fiscal year
      ended January 31, 2007 was $7,500. Our current principal accountant also
      reviewed our quarterly reports on Form 10-QSB during the fiscal year ended
      January 31, 2007. The aggregate fees, including expenses in connection with
      the
      review of our financial information included in our quarterly reports on Form
      10-QSB during the fiscal year ending January 31, 2007 was $4,500.




Audit
      Related Fees: The aggregate fees, including expenses, billed by our principal
      accountant for services reasonably related to the audit for the year ended
      January 31, 2007 was $-0-.




Tax
      Fees:
      The aggregate fees, billed by our principal accountant for services reasonably
      related to tax services during the year ended January 31, 2007 was
      $-0-.




All
      Other
      Fees:  The aggregate fees, including expenses, billed for all other
      services rendered to us by our principal accountant during fiscal year 2007
      was
      $-0-.




**Year
      ended January 31, 2006**




Audit
      Fees:   The aggregate fees, including expenses, billed by our current
      principal accountant in connection with the audit of our consolidated financial
      statements for the most recent fiscal year and for the review of our financial
      information included in our Annual Report on Form 10-KSB for the fiscal year
      ended January 31, 2006 was $7,500. The aggregate fees, including expenses,
      billed by our principal accountant in connection with the review of our
      financial information included in our quarterly reports on Form 10-QSB during
      the fiscal year ending January 31, 2006 was $0.




Audit
      Related Fees: The aggregate fees, including expenses, billed by our principal
      accountant for services reasonably related to the audit for the year ended
      January 31, 2006 was $-0-.




Tax
      Fees:
      The aggregate fees, billed by our principal accountant for services reasonably
      related to tax services during the year ended January 31, 2006 was
      $-0-.




All
      Other
      Fees:  The aggregate fees, including expenses, billed for all other
      services rendered to us by our principal accountant during fiscal year 2006
      was
      $-0-.




The
      Company’s Board of Directors acts as an audit committee. The Board of Directors
      has considered whether the provisions of the services covered above under the
      captions is compatible with maintaining the auditor’s independence and approved
      such services prior to the services being provided.




12


**SIGNATURES**




In
      accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934,
      as
      amended, the registrant caused this report to be signed on its behalf by the
      undersigned and duly authorized on October 11, 2007.


**LIFESCIENCES
              OPPORTUNITIES INCORPORATED**By:
            /s/ Roland
              PerryRoland
              PerryPresident
              and
              Chief Executive Officer(Principal
                Executive Officer and
              Principal
                Financial Officer)


13